Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Public Health Advocacy topic
No spam. Unsubscribe anytime.
Local survivor urges expanded lung cancer screening and research funding at Huntersville meeting
Summary
A Huntersville resident speaking during public comment described a lung cancer diagnosis at age 42 and urged expanded screening eligibility and more research funding, noting that many patients have never smoked and face insurance barriers to targeted therapies.
A Huntersville resident who identified herself as Julie spoke during public comment at the May 20 Town Board meeting about lung cancer awareness and screening. She said she was diagnosed with lung cancer at age 42 with no risk factors and that the cancer was found incidentally during a calcium‑score heart scan.
Julie described her treatment experience, including removal of half of her left lung and ongoing targeted therapy, and said the monthly cost of her medication is "several thousand dollars a month" and that she repeatedly encounters insurance hurdles for refills. She told the board that lung cancer kills more people than breast, prostate and colon cancer combined and that lung cancer receives less than 10 percent of cancer research funding overall. "My story is not rare," she said, noting that an estimated 20 percent of lung cancer patients have never smoked and another 40 percent were former smokers.
Julie urged broader access to screening and said the current CT screening eligibility discussed at the meeting is limited to people 50 and older with a smoking history, which excludes roughly half of lung cancer patients by her estimate. She encouraged listeners who may be eligible to visit savebythescan.org and suggested clinicians consider calcium‑score heart scans as an incidental screening pathway when appropriate. She called for greater awareness and for state coverage of biomarker testing to support precision treatment decisions.
Her remarks were offered as a personal account and advocacy appeal during the public‑comment period; the board did not take formal action on screening or research funding at the May 20 meeting.
